RxDoctor Payments Data

John McCarthy

Infectious Disease · Whittier, CANPI 1679650923

Payments from drug & device makers

$638in general payments, 2019–2025

Across 18 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$216
  • Shionogi Inc$154
  • Insmed, Inc.$75
  • Viiv Healthcare Company$37
  • Astellas Pharma US Inc$29
  • Boston Scientific$29
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$27543%
  • Education$36357%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$638 in reported general payments places this provider in the 55th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$116,649
Medicare patients
188
Services billed
1,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala76$305,800
DescovyEmtricitabine/Tenofov Alafenam26$59,097
IsentressRaltegravir Potassium17$55,631
DovatoDolutegravir Sodium/Lamivudine11$32,178
Etravirine16$26,212
TivicayDolutegravir Sodium12$23,958
EliquisApixaban22$12,672
Vancomycin Hcl67$8,604
CeftriaxoneCeftriaxone Sodium48$7,574
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)12$4,027
Ceftazidime30$3,504
Cephalexin95$1,899
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav73$1,682
Levofloxacin94$1,528
Ciprofloxacin Hcl57$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$14$364,897102 claims
Viiv Healthcare CompanyDovato, Tivicay$37$56,13623 claims
MerckIsentress$28$55,63117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 856 infectious disease providers in California.

Other infectious disease in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →